Updated safety results from a cohort compassionate-use programme (CUP) and early access programme (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D)
Author
Ardavanis, A.
Basaran, M.
Malik, Z. I.
Di Lorenzo, G.
Heidenreich, A.
Hitier, S.
Van Oort, I.
Saad, F.
De Schultz, W.
Parente, P.
Metadata
Show full item recordCollections
- Bildiri [64839]